Abstract
Introduction
Combining antihyperglycemic agents with complementary mechanisms of action is a cornerstone of type 2 diabetes mellitus (T2DM) management. Although several fixed-dose combinations (FDCs) are available, representing standard types of combination therapy in T2DM, use of these products has been limited.
Methods
To address the likely concerns of prescribers and patients regarding the use of FDCs in the treatment of T2DM, literature searches were performed to ascertain the bioavailability, efficacy, tolerability, and cost-effectiveness of the currently approved FDCs compared with their individual component drugs given as separate pills in combination. Additionally, data were collected on rates of adherence, clinical outcomes, and overall treatment costs with FDCs versus dual therapy with the same constituent drugs.
Results
Bioavailability is equivalent for FDCs and dual therapy used in T2DM. Efficacy and tolerability also appear to be at least as good with FDCs as with dual therapy. Retrospective analyses have suggested that FDCs can enhance adherence to therapy, presumably as a result of the reduction in pill burden, and improved adherence may result in improved glycemic control and reduced disease management costs. In addition, because currently available FDCs come in two or more dose-strength formulations, they also afford some measure of dosing flexibility.
Conclusions
The available evidence supports the wider use of FDCs in the treatment of patients with T2DM.
Article PDF
Similar content being viewed by others
References
Moulding T, Dutt AK, Reichman LB. Fixed-dose combinations of antituberculous medications to prevent drug resistance. Ann Intern Med. 1995;122:951–954.
METAGLIP® (glipizide and metformin hydrochloride). Full prescribing information, Bristol-Myers Squibb, Princeton, NJ. 2009. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021460s007lbl.pdf. Accessed December 23, 2011.
PRANDIMET® (repaglinide and metformin hydrochloride). Full prescribing information, Novo Nordisk, Princeton, NJ. 2010. Available at: http://www.novo-pi.com/prandimet.pdf. Accessed December 23, 2011.
AVANDAMET® (rosiglitazone and metformin hydrochloride). Full prescribing information, GlaxoSmithKline, Research Triangle Park, NC. 2008. Available at: http://us.gsk.com/products/assets/us_avandamet.pdf. Accessed December 23, 2011.
JANUMET® (sitagliptin and metformin hydrochloride). Full prescribing information, Merck & Co, Whitehouse Station, NJ. 2010. Available at: http://www.merck.com/product/usa/pi_circulars/j/janumet/janumet_pi.pdf. Accessed December 23, 2011.
ACTOPLUS MET® (pioglitazone hydrochloride and metformin hydrochloride) and ACTOPLUS MET XR® (pioglitazone hydrochloride and metformin hydrochloride extended-release). Full prescribing information, Takeda Pharmaceuticals America, Inc., Deerfield, IL, 2010. Available at: http://general.takedapharm.com/content/file/pi.pdf?applicationcode=8a9c4571-a123-4477-91de-b9cafe7d07e3&filetypecode=ACTOPLUSMET PI; http://general.takedapharm.com/content/file/pi.pdf?applicationcode=8a9c4571-a123-4477-91de-b9cafe7d07e3&filetypecode=ACTOPLUSMETXRPI. Accessed December 23, 2011.
AVANDARYL® (rosiglitazone and glimepiride). Full prescribing information, GlaxoSmithKline, Research Triangle Park, NC. 2009. Available at: http://us.gsk.com/products/assets/us_avandaryl. pdf. Accessed December 23, 2011.
DUETACT® (pioglitazone and glimepiride). Full prescribing information, Takeda Pharmaceuticals America, Deerfield, IL. 2010. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021925s010s011lbl.pdf. Accessed December 23, 2011.
KOMBIGLYZE XR® (saxagliptin and extended-release metformin hydrochloride). Full prescribing information, Bristol-Myers Squibb, Princeton, NJ. 2010. Available at: http://packageinserts.bms.com/pi/pi_kombiglyze_xr.pdf. Accessed December 23, 2011.
GLUCOVANCE® (glyburide and metformin hydrochloride). Full prescribing information, Bristol-Myers Squibb, Princeton, NJ. 2010. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021178s012lbl.pdf. Accessed December 23, 2011.
Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–795.
Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005–2012.
Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27:1535–1540.
Riedel AA, Heien H, Wogen J, Plauschinat CA. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy. 2007;27:1102–1110.
Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203.
Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540–559.
Hollander PA, Kushner P. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. Postgrad Med. 2010;122:71–80.
Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med. 2008;23:611–614.
Cheong C, Barner JC, Lawson KA, Johnsrud MT. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. Clin Ther. 2008;30:1893–1907.
Thayer S, Arondekar B, Harley C, Darkow TE. Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea. Ann Pharmacother. 2010;44:791–799.
Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther. 2002;24:460–467.
Williams B, Shaw A, Durrant R, Crinson I, Pagliari C, de Lusignan S. Patient perspectives on multiple medications versus combined pills: a qualitative study. QJM. 2005;98:885–893.
Garber AJ, Larsen J, Schneider SH, Piper BA, Henry D. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab. 2002;4:201–208.
Perez A, Zhao Z, Jacks R, Spanheimer R. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM. Curr Med Res Opin. 2009;25:2915–2923.
Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2006;8:650–660.
Chou HS, Palmer JP, Jones AR, et al. Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes. Diabetes Obes Metab. 2008;10:626–637.
Goldstein BJ, Pans M, Rubin CJ. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. Clin Ther. 2003;25:890–903.
Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 1999;22:119–124.
Jadzinsky M, Pfutzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11:611–622.
Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30:1979–1987.
Blonde L, Wogen J, Kreilick C, Seymour AA. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab. 2003;5:424–431.
Gold DT, McClung B. Approaches to patient education: emphasizing the long-term value of compliance and persistence. Am J Med. 2006;119:S32–37.
Lawrence DB, Ragucci KR, Long LB, Parris BS, Helfer LA. Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1C goal attainment for HMO patients enrolled in a diabetes disease management program. J Manag Care Pharm. 2006;12:466–471.
Pladevall M, Williams LK, Potts LA, Divine G, Xi H, Lafata JE. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care. 2004;27:2800–2805.
Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166:1836–1841.
Saleh SS, Szebenyi S, Carter JA, Zacher C, Belletti D. Patterns and associated health services costs of antihypertensive drug modifications. J Clin Hypertens (Greenwich). 2008;10:43–50.
Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm. 2007;64:1279–1283.
Balu S, Simko RJ, Quimbo RM, Cziraky MJ. Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence. Curr Med Res Opin. 2009;25:2765–2775.
Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713–719.
Brixner DI, Jackson KC 2nd, Sheng X, Nelson RE, Keskinaslan A. Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations. Curr Med Res Opin. 2008;24:2597–2607.
Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a Medicaid patient population with type 2 diabetes mellitus. Clin Ther. 2001;23:1311–1320.
Dailey G, Kim MS, Lian JF. Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of type 2 diabetic patients. J Int Med Res. 2002;30:71–79.
Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med. 2002;19:279–284.
Guillausseau PJ. Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. A survey in general practice. Diabetes Metab. 2003;29:79–81.
Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care. 1997;20:1512–1517.
National Diabetes Information Clearinghouse. National Diabetes Statistics, 2007. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, US Department of Health and Human Services, National Institutes of Health; 2008. NIH Publication No. 08-3892.
Salas M, Hughes D, Zuluaga A, Vardeva K, Lebmeier M. Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature. Value Health. 2009;12:915–922.
Rabbani A, Alexander GC. Out-of-pocket and total costs of fixed-dose combination antihypertensives and their components. Am J Hypertens. 2008;21:509–513.
Angus DC, Linde-Zwirble WT, Tam SW, et al. Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure. Circulation. 2005;112:3745–3753.
Hess G, Hill J, Lau H, Dastani H, Chaudhari P. Medication utilization patterns and hypertension-related expenditures among patients who were switched from fixed-dose to free-combination antihypertensive therapy. P T. 2008;33:652–666.
Author information
Authors and Affiliations
Corresponding author
Additional information
To view enhanced content go to www.advancesintherapy.com
This article is published with open access at Springerlink.com
An erratum to this article can be found online at http://dx.doi.org/10.1007/s12325-013-0017-4.
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Blonde, L., San Juan, Z.T. Fixed-Dose Combinations for Treatment of Type 2 Diabetes Mellitus. Adv Therapy 29, 1–13 (2012). https://doi.org/10.1007/s12325-011-0094-1
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-011-0094-1